Events Learning is an infinite game. That's why we support the most prestigious annual medical conferences – where knowledge is shared for the benefit of all.

Bracco’s HeartSee: New Features for CAD Diagnosis and Ease of Use Bracco Diagnostics Inc. announced today significant upgrades to its innovative HeartSeeTM software, a leading diagnostic tool used in myocardial blood flow (MBF) quantification with cardiac positron emission tomography (PET) imaging.

The Bracco Foundation: A culture based on values The origins of the Bracco Foundation lie in the heritage of values passed down for nearly a century from the Bracco family and the Bracco Group, fostering a sense of Corporate Social Responsibility. The Foundation aims to create and spread expressions of culture, art, and science as means for improving our quality of life. It pays specific attention to women and younger generations, encouraging social cohesion.

New Nationwide Real-World Data Validates the Safety of LUMASON® UEA in Contemporary Echocardiographic Practice Bracco Diagnostics Inc. announced today that the results of a nationwide real-world study, published by Dr. Strom et al. in the Journal of the American Heart Association on 14 May 2025, provide valuable information on safety outcomes of cardiac ultrasound procedures in contemporary practice in the United States.

Bracco Imaging earns its first EcoVadis Platinum Medal: in Global Top 1%

Join us @ RSNA 2025 At RSNA 2025, Bracco Diagnostics Inc. is proud to spotlight its unwavering dedication to two distinct pillars shaping the future of radiology: education and sustainability. 

RSNA 2025 - Cloned

Scientific Information Inquiry Fill in this form to receive information about medical and clinical aspects of a product.

Bracco Shapes the Future of Radiology at RSNA 2025 Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, will showcase a bold vision for radiology at the Radiological Society of North America (RSNA) 2025 Annual Meeting, to be held November 30 – December 4 in Chicago, Illinois.

Bracco Delivers 3 Million VUEWAY® Doses, Meeting Patient Demand for Lower-Dose MRI Contrast Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that more than three million doses1 of its magnetic resonance imaging (MRI) agent, VUEWAY® (gadopiclenol) solution for injection, intravenous use, have been administered across 902 customer sites.2